Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC

Humberto C. González; Stuart C. Gordon; Sheri Trudeau; Trueman Wu; Lora Rupp; Christina Melkonian; Mark A. Schmidt; Yihe G. Daida; Amandeep Sahota; Christopher L. Bowlus; M. C. Lu

doi:10.1111/liv.70628

April 3, 2026Liver InternationalOpen Access

Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the relationship between disease-specific treatments and the risk of portal vein thrombosis (PVT) in cirrhotic patients with HCV or PBC.
Analyzed two large samples of cirrhotic patients with HCV or PBC.
Examined the association between disease-specific treatments and PVT risk.
Assessed the impact of non-selective beta blocker (NSBB) treatment on PVT risk across different patient statuses.
Disease-specific treatments did not show any correlation with PVT risk.
Patients treated with NSBB had over two times the risk of developing PVT in both patient samples.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Two samples show non-selective beta blockers increase PVT risk in cirrhotic patients, suggesting treatment caution.

Abstract

In two large well-characterized samples of cirrhotic patients with HCV or PBC, disease-specific treatments were not associated with PVT risk. NSBB treatment was independently associated with > 2 times the risk of PVT in both samples, regardless of compensated or decompensated status.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

González et al. (2026) studied this question.

synapsesocial.com/papers/69d34dd49c07852e0af97760 https://doi.org/10.1111/liv.70628

View Full Paper

Ask AI

Bookmark

Share

Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading